Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Shanghai Bao Pharmaceuticals Co. Ltd. has 2 pending office actions in Chemistry & Materials. The matters are assigned to 2 distinct examiners and 2 distinct art units, reflecting separate examination tracks.
FAN, LYNN Y is the busiest examiner, with 1 pending office action. Counsel can manage the actions independently while maintaining separate examiner and art-unit response records.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FAN, LYNN Y | 1 | 47.3% | +49.8% |
| PETERS, ALEC JON | 1 | 67.4% | +54.8% |
| DABKOWSKI, ERINNE R | 1 | 55.8% | +68.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260079 | RECOMBINANT HUMAN HYALURONIDASE FORMULATION AND APPLICATION THEREOF | FAN, LYNN Y | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260079 | RECOMBINANT HUMAN HYALURONIDASE FORMULATION AND APPLICATION THEREOF | FAN, LYNN Y | — |
| 18000516 | PHARMACEUTICAL COMPOSITION OF ENZYMES AND VIRUSES AND APPLICATION THEREOF | PETERS, ALEC JON | — |
| 18027755 | PHARMACEUTICAL COMBINATION AND USE THEREOF | DABKOWSKI, ERINNE R | — |
| Art Unit | Apps |
|---|---|
| 1759 | 1 |
| 1641 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18260079 | RECOMBINANT HUMAN HYALURONIDASE FORMULATION AND APPLICATION THEREOF | FAN, LYNN Y | 1759 | §103§112 | Non-Final OA | — | Pending | Jun 30, 2023 |
| 18000516 | PHARMACEUTICAL COMPOSITION OF ENZYMES AND VIRUSES AND APPLICATION THEREOF | PETERS, ALEC JON | 1641 | §103 | Non-Final OA | — | Pending | May 26, 2023 |
| 18027755 | PHARMACEUTICAL COMBINATION AND USE THEREOF | DABKOWSKI, ERINNE R | 1654 | §112Other | Final Rejection | — | Pending | May 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShanghai Bao Pharmaceuticals Co. Ltd. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Lynn Y Fan has the most, with 1 of Shanghai Bao Pharmaceuticals Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
